Twist Bioscience to Acquire Abveris for ~$190M

Share this


Twist Bioscience to Acquire Abveris for ~$190M


  • Twist to acquire Abveris for a total consideration of $190M including $150M at the closing of the transaction and $10M in cash, $40M at shares of Twist common stock

  • The acquisition will complement & expand Twist’s biopharma Ab capabilities into mouse-based discovery and screening with the addition of Abveris in vivo Ab discovery platform for the development of therapies

  • Abveris provides comprehensive Ab discovery and characterization services using its DiversimAb platform which can be humanized using the Twist antibody optimization solution to develop superior biologics for clinical advancement

Ref: Twist Bioscience| Image: Twist Bioscience


This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions